

## Paradigm Shift: Preliminary Clinical Categorization of Ultrahigh Risk for Childhood Bipolar Disorder to Facilitate Studies on Prevention

Robert M. Post, MD; Kiki Chang, MD; and Mark A. Frye, MD

Recent epidemiologic data suggest an approximate 2.5% incidence of bipolar spectrum disorder in adolescents,<sup>1,2</sup> and retrospective data in adults (mean age = 42 years) in the United States suggest that the onset of bipolar illness occurs in childhood prior to age 13 in one-fourth to one-fifth of cases.<sup>3,4</sup> The data converge with a variety of other studies in clinical populations indicating that pediatric-onset bipolar disorder is common, highly disabling, difficult to treat,<sup>5-10</sup> and prone to relapse.<sup>11-20</sup> Moreover, one-third of well-diagnosed children during an 8-year follow-up of naturalistic treatment in the community never received any of the recommended pharmacologic treatments for bipolar disorder.<sup>16</sup>

Given the very considerable morbidity and dysfunction associated with childhood-onset bipolar illness, early identification and treatment remain a very high but elusive priority. Childhood-onset illness is associated with a more adverse outcome in adulthood than adult-onset illness.<sup>3,4,21,22</sup> In addition, the duration of the time lag to first treatment is an independent risk factor for a poor outcome in adulthood.<sup>3</sup> More specifically, acute response rates to the gold standard mood stabilizer lithium are reduced with increased prior episode burden, suggesting that undiagnosed or poorly treated adolescent bipolar disorder reduces the response for successful outcome for adults treated with lithium.<sup>23</sup> The public health implications of nonresponse, general morbidity, and financial costs are staggering: \$11,720 for persons with a single manic episode versus \$624,785 for those with nonresponsive illness.<sup>24</sup>

Further confounding attempts at early intervention are the paucity of studies delineating optimal treatment approaches even for children meeting full criteria for bipolar I disorder.<sup>25-27</sup> While quetiapine, aripiprazole, and risperidone have been approved by the US Food and Drug Administration (FDA) for children from 10 to 17 years of age with bipolar I disorder, olanzapine has been approved for adolescents aged 13-17, and lithium "grandfathered" in children older than 12, treatment sequences and algorithms have not been well studied and depend on expert opinion.<sup>25,26,28</sup> Treatment for children with bipolar II disorder and bipolar disorder not otherwise specified (NOS) has rarely been studied.

*Submitted:* August 28, 2012; *accepted:* November 16, 2012.

*Corresponding author:* Robert M. Post, MD, Bipolar Collaborative Network, 5415 West Cedar Ln Ste 201B, Bethesda, MD 20814 (robert.post@speakeasy.net).

*J Clin Psychiatry* 2013;74(2):167-169 (doi:10.4088/JCP.12com08136).  
© Copyright 2013 Physicians Postgraduate Press, Inc.

A recent study sponsored by the National Institute of Mental Health found that the atypical antipsychotic risperidone was substantially more effective than either lithium or divalproex in the treatment of childhood-onset mania,<sup>29</sup> yet tolerability problems were seen in the domains of weight gain, prolactin increases, and sedation. Comparative study with other better-tolerated atypical antipsychotics is now an urgent but completely unmet need.

We suggest that high risk and ultrahigh risk for childhood-onset bipolar disorder can already be preliminarily delineated for children on clinical grounds prior to the ascertainment of other more slowly forthcoming neurobiological measures. In this fashion, information about those with ultrahigh-risk status can be utilized to begin to explore the effectiveness of approaches to primary and secondary prevention in young children.

This strategy could lead to an iterative process in which clinical and biological markers of illness onset and progression could then be reassessed as the field matures and more data become available. As more neurobiological markers begin to be assessed and validated, the clinical categorizations of these early provisional high-risk and ultrahigh-risk children could be revised accordingly. Finally, these same predictors of onset of illness and course of illness markers could be reinvestigated for potential prediction of individual response to individual treatments in those who do become ill.

Recent data suggest that parental report of treatment outcome is an excellent alternative approach to treatment outcome rated by other trained observers. This approach also converges with the data that parental reports on the symptoms necessary for a diagnosis of childhood-onset bipolar illness are more reliable and valid than those from teachers or the young children themselves,<sup>30-32</sup> and repeated parental report of symptoms is helpful in making a bipolar diagnosis.<sup>33</sup> Greater reliance on parental evaluations would minimize costs and allow the development of Web-based comparative effectiveness trials.

Parental illness variables are one set of clear risk factors for early-onset bipolar disorder. Parental history of bipolar disorder increases the risk of bipolar disorder in the offspring to approximately 20% and for any affective disorder or psychiatric illness even farther.<sup>11,34</sup> If, however, both parents are affected (one with bipolar disorder and the other with either bipolar or unipolar disorder), the risk for an affective disorder in the offspring increases to about 70%.<sup>35</sup> If, in addition, one or both of the parents were also actively ill, this occurrence would very likely increase the rate of psychiatric disorder even further in the offspring,<sup>36-38</sup> as would a positive parental

history of an alcohol or substance abuse disorder or a serious suicide attempt.<sup>36–38</sup>

Environmental risk factors for childhood bipolar disorder have also been identified and include preterm delivery,<sup>39</sup> childhood adversity,<sup>40–42</sup> the presence of other childhood psychiatric conditions, and prodromal symptoms or a bipolar disorder NOS diagnosis.<sup>6,8</sup> Thus, a case can be made that a preliminary delineation of high- and ultrahigh-risk categories based on parental, environmental, and symptom variables could be made on clinical grounds now that would allow the initiation of studies of primary (prior to illness onset) and secondary (after first symptoms/episode) preventive interventions in those at highest risk.

Given this type of provisional very high-risk status (rating sheet available upon request), particularly if the child were already prodromal or syndromal with bipolar disorder NOS, the idea of active treatment interventions becomes compelling from both a clinical care and an ethical perspective. If one begins to utilize the comparison of 2 putatively active, safe, and well-tolerated pharmacologic or psychotherapeutic modalities in clinical trials, parents would be highly likely to want their children to participate in such studies.<sup>43</sup> Such preventive interventions could include systematic exploration of different psychotherapeutic approaches and pharmacologic agents, including vitamins, a micronutrient formula (such as EMPowerplus), omega-3 fatty acids, and *N*-acetylcysteine.

Finally, this study of primary and secondary prevention in open studies in childhood-onset bipolar disorder, initially based only on clinically derived factors, also opens the possibility of later utilizing these same existing cohorts to facilitate the definition of neurobiological markers of onset risk, course of illness, and ultimately response to treatment prediction. A large number of medications are already being widely utilized in the community, yet the long-term outcome of the use of these agents alone or in combination—effectiveness, tolerability, or prediction of individual response—has rarely been systematically studied.

As argued by many investigators, the utilization of practical clinical trials could not only accelerate the generation of clinically useful information but also potentially accelerate the development of clinical and biological markers.<sup>44–48</sup> The traditional gold standard, a randomized, controlled clinical trial with a placebo parallel group, is ideal for the generation of FDA-approval status and licensing of a drug but is extraordinarily expensive, cumbersome, and deficient in generating either optimal clinical treatment strategies or markers of clinical response.<sup>48</sup>

We are suggesting that large numbers of subjects could be identified and studied in the community as in clinical trials in cancer therapeutics but at a markedly reduced cost. Both risk status and follow-up of the effectiveness and tolerability of the interventions would initially be highly dependent on parental report in order to free clinicians in busy clinical practices to be able to participate with a minimal time commitment.

Multiple sites and international consortia are currently examining formal, double-blind methods of evaluating potential neurobiological markers of bipolar illness, onset, progression, and response to treatment, but these efforts are using highly diverse measures and methods, are inconsistent across sites, and are extraordinarily expensive. Even if a whole host of neurobiological markers becomes available in the not-too-distant future, this would still leave the field at a loss as to how to begin to explore potential primary and secondary preventive treatments and to pursue tertiary preventive treatment strategies once full-blown illness has already been identified.

The current proposal could help overcome many of these logistical, methodological, recruitment, and financial obstacles. Large numbers of young subjects at ultrahigh risk could be rapidly identified in the community, and if parents desired it, enrolled in open preventative comparative clinical trials of 2 very safe modalities in clinical practice settings. Dispensing of interventional agents would be accompanied by basic psychotherapeutic and behavioral recommendations (eg, good sleep hygiene, exercise and diet recommendations, and basic stress coping skills) to enhance care in all participants.

Participating academic centers could simultaneously validate parental ratings with other more detailed measures that they are using and add new candidate neurobiological markers for investigation. As the subgroup of high-risk children who become syndromal is treated in the same clinical practice settings, the risk markers could then be reevaluated for their potential prediction of individual clinical response to individual drugs. An iterative process would take place as preliminary clinical treatment response data would be replicated and putative predictors of response augmented by new neurobiological candidates as new information became available.

Thus, rather than having an expensive, time-consuming sequence of examining possible markers in initial double-blind, placebo-controlled studies and then performing cumbersome validation studies (which may never be adequately funded), we suggest a more accelerated and streamlined project starting with children readily identified clinically to be at very high risk and preliminarily evaluating the safest preventive treatments and then the safest acute treatments in those who become ill. This paradigm shift could rapidly produce a wealth of preliminary data on effectiveness and safety of early preventive and treatment strategies while facilitating the acquisition, revision, and accretion of new clinical and neurobiological markers.

**Drug names:** aripiprazole (Abilify), divalproex sodium (Depakote and others), lithium (Lithobid and others), olanzapine (Zyprexa), quetiapine (Seroquel), risperidone (Risperdal and others).

**Author affiliations:** Bipolar Collaborative Network, Bethesda, Maryland (Dr Post); Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California (Dr Chang); and Department of Psychiatry and Psychology and Mayo Clinic Depression Center, Mayo Clinic, Rochester, Minnesota (Dr Frye).

**Potential conflicts of interest:** Dr Post has served as a consultant for AstraZeneca, Validus, Sunovion, Teva, and Puretech and has served on the speakers board for AstraZeneca. Dr Chang has served as a consultant for Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Merck and has received grant/research support from GlaxoSmithKline and Merck. Dr Frye has received grant/research support from Pfizer, Myriad, the National Alliance for Schizophrenia and Depression, the National Institute of Mental Health, and the National Institute on Alcohol Abuse and Alcoholism and has received CME

travel support from GlaxoSmithKline, Bristol-Myers Squibb, Sanofi-Aventis, and AstraZeneca.

**Funding/support:** None reported.

**REFERENCES**

1. Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. *Arch Gen Psychiatry*. 2011;68(3):241–251.
2. Merikangas KR, He JP, Burstein M, et al. Service utilization for lifetime mental disorders in US adolescents: results of the National Comorbidity Survey-Adolescent Supplement (NCS-A). *J Am Acad Child Adolesc Psychiatry*. 2011;50(1):32–45.
3. Post RM, Leverich GS, Kupka RW, et al. Early-onset bipolar disorder and treatment delay are risk factors for poor outcome in adulthood. *J Clin Psychiatry*. 2010;71(7):864–872.
4. Perlis RH, Miyahara S, Marangell LB, et al, and the STEP-BD Investigators. Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). *Biol Psychiatry*. 2004;55(9):875–881.
5. Birmaher B, Axelson D. Course and outcome of bipolar spectrum disorder in children and adolescents: a review of the existing literature. *Dev Psychopathol*. 2006;18(4):1023–1035.
6. Birmaher B, Axelson D, Goldstein B, et al. Four-year longitudinal course of children and adolescents with bipolar spectrum disorders: the Course and Outcome of Bipolar Youth (COBY) study. *Am J Psychiatry*. 2009;166(7):795–804.
7. Birmaher B, Axelson D, Strober M, et al. Clinical course of children and adolescents with bipolar spectrum disorders. *Arch Gen Psychiatry*. 2006;63(2):175–183.
8. Birmaher B, Axelson D, Strober M, et al. Comparison of manic and depressive symptoms between children and adolescents with bipolar spectrum disorders. *Bipolar Disord*. 2009;11(1):52–62.
9. Birmaher B, Williamson DE, Dahl RE, et al. Clinical presentation and course of depression in youth: does onset in childhood differ from onset in adolescence? *J Am Acad Child Adolesc Psychiatry*. 2004;43(1):63–70.
10. Findling RL, Gracious BL, McNamara NK, et al. Rapid, continuous cycling and psychiatric co-morbidity in pediatric bipolar I disorder. *Bipolar Disord*. 2001;3(4):202–210.
11. DelBello M, Grcevich S. Phenomenology and epidemiology of childhood psychiatric disorders that may necessitate treatment with atypical antipsychotics. *J Clin Psychiatry*. 2004;65(suppl 6):12–19.
12. DelBello MP. Can research inform the clinical care of mental health disorders in children and adolescents? *J Clin Psychiatry*. 2007;68(2):296.
13. DelBello MP, Hanseman D, Adler CM, et al. Twelve-month outcome of adolescents with bipolar disorder following first hospitalization for a manic or mixed episode. *Am J Psychiatry*. 2007;164(4):582–590.
14. Geller B, Craney JL, Bolhofner K, et al. One-year recovery and relapse rates of children with a prepubertal and early adolescent bipolar disorder phenotype. *Am J Psychiatry*. 2001;158(2):303–305.
15. Geller B, Craney JL, Bolhofner K, et al. Two-year prospective follow-up of children with a prepubertal and early adolescent bipolar disorder phenotype. *Am J Psychiatry*. 2002;159(6):927–933.
16. Geller B, Tillman R, Bolhofner K, et al. Child bipolar I disorder: prospective continuity with adult bipolar I disorder; characteristics of second and third episodes; predictors of 8-year outcome. *Arch Gen Psychiatry*. 2008;65(10):1125–1133.
17. Geller B, Tillman R, Bolhofner K, et al. Pharmacological and non-drug treatment of child bipolar I disorder during prospective eight-year follow-up. *Bipolar Disord*. 2010;12(2):164–171.
18. Geller B, Tillman R, Craney JL, et al. Four-year prospective outcome and natural history of mania in children with a prepubertal and early adolescent bipolar disorder phenotype. *Arch Gen Psychiatry*. 2004;61(5):459–467.
19. Wozniak J. Recognizing and managing bipolar disorder in children. *J Clin Psychiatry*. 2005;66(suppl 1):18–23.
20. Wozniak J, Petty CR, Schreck M, et al. High level of persistence of pediatric bipolar-I disorder from childhood onto adolescent years: a four year prospective longitudinal follow-up study. *J Psychiatr Res*. 2011;45(10):1273–1282.
21. Perlis RH, Dennehy EB, Miklowitz DJ, et al. Retrospective age at onset of bipolar disorder and outcome during two-year follow-up: results from the STEP-BD study. *Bipolar Disord*. 2009;11(4):391–400.
22. Carter TD, Mundo E, Parikh SV, et al. Early age at onset as a risk factor for poor outcome of bipolar disorder. *J Psychiatr Res*. 2003;37(4):297–303.
23. Frye MA, Ketter TA, Altschuler LL, et al. Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics. *J Affect Disord*. 1998;48(2-3):91–104.
24. Begley CE, Annegers JF, Swann AC, et al. The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. *Pharmacoeconomics*. 2001;19(5, pt 1):483–495.
25. Kowatch RA, DelBello MP. Pharmacotherapy of children and adolescents with bipolar disorder. *Psychiatr Clin North Am*. 2005;28(2):385–397.
26. Kowatch RA, Fristad M, Birmaher B, et al, and the Child Psychiatric Workgroup on Bipolar Disorder. Treatment guidelines for children and adolescents with bipolar disorder. *J Am Acad Child Adolesc Psychiatry*. 2005;44(3):213–235.
27. Kowatch RA, Youngstrom EA, Danielyan A, et al. Review and meta-analysis of the phenomenology and clinical characteristics of mania in children and adolescents. *Bipolar Disord*. 2005;7(6):483–496.
28. Post RM, Wozniak J. Survey of expert treatment approaches for children with bipolar disorder not otherwise specified and bipolar I presentations. *Psychiatr Ann*. 2009;39(10):887–895.
29. Geller B, Luby JL, Joshi P, et al. A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. *Arch Gen Psychiatry*. 2012;69(5):515–528.
30. Youngstrom EA, Findling RL, Calabrese JR. Effects of adolescent manic symptoms on agreement between youth, parent, and teacher ratings of behavior problems. *J Affect Disord*. 2004;82(suppl 1):S5–S16.
31. Youngstrom EA, Freeman AJ, Jenkins MM. The assessment of children and adolescents with bipolar disorder. *Child Adolesc Psychiatr Clin N Am*. 2009;18(2):353–390.
32. Youngstrom EA, Joseph MF, Greene J. Comparing the psychometric properties of multiple teacher report instruments as predictors of bipolar disorder in children and adolescents. *J Clin Psychol*. 2008;64(4):382–401.
33. Frazier TW, Youngstrom EA, Horwitz SM, et al. Relationship of persistent manic symptoms to the diagnosis of pediatric bipolar spectrum disorders. *J Clin Psychiatry*. 2011;72(6):846–853.
34. Chang KD, Steiner H, Ketter TA. Psychiatric phenomenology of child and adolescent bipolar offspring. *J Am Acad Child Adolesc Psychiatry*. 2000;39(4):453–460.
35. Lalpalm M, Hodgins S, LaRoche C. Children of parents with bipolar disorder: a meta analysis of risk for mental disorders. *Can J Psychiatry*. 1997;42(6):623–631.
36. Brent DA, Oquendo M, Birmaher B, et al. Familial pathways to early-onset suicide attempt: risk for suicidal behavior in offspring of mood-disordered suicide attempters. *Arch Gen Psychiatry*. 2002;59(9):801–807.
37. Brent DA, Oquendo M, Birmaher B, et al. Peripubertal suicide attempts in offspring of suicide attempters with siblings concordant for suicidal behavior. *Am J Psychiatry*. 2003;160(8):1486–1493.
38. Brent DA, Oquendo M, Birmaher B, et al. Familial transmission of mood disorders: convergence and divergence with transmission of suicidal behavior. *J Am Acad Child Adolesc Psychiatry*. 2004;43(10):1259–1266.
39. Nosarti C, Reichenberg A, Murray RM, et al. Preterm birth and psychiatric disorders in young adult life. *Arch Gen Psychiatry*. 2012;69(6):e1–e8.
40. Leverich GS, McElroy SL, Suppes T, et al. Early physical and sexual abuse associated with an adverse course of bipolar illness. *Biol Psychiatry*. 2002;51(4):288–297.
41. Post RM, Miklowitz DJ. The role of stress in the onset, course, and progression of bipolar illness and its comorbidities: implications for therapeutics. In: Miklowitz DJ, and Cicchetti D, eds. *Understanding Bipolar Disorder: A Developmental Psychopathology Perspective*. New York, New York: Guilford Press; 2010: 370–413.
42. Shonkoff JP, Garner AS, the Committee on Psychosocial Aspects of Child and Family Health, et al, and the Section on Developmental and Behavioral Pediatrics. The lifelong effects of early childhood adversity and toxic stress. *Pediatrics*. 2012;129(1):e232–e246.
43. Post RM, Leverich GS, Fergus E, et al. Parental attitudes towards early intervention in children at high risk for affective disorders. *J Affect Disord*. 2002;70(2):117–124.
44. March J, Kraemer HC, Trivedi M, et al. What have we learned about trial design from NIMH-funded pragmatic trials? *Neuropsychopharmacology*. 2010;35(13):2491–2501.
45. March JS, Silva SG, Compton S, et al. The case for practical clinical trials in psychiatry. *Am J Psychiatry*. 2005;162(5):836–846.
46. Post RM, Luckenbaugh DA. Unique design issues in clinical trials of patients with bipolar affective disorder. *J Psychiatr Res*. 2003;37(1):61–73.
47. Stroup TS. What can large simple trials do for psychiatry? *Am J Psychiatry*. 2011;168(2):117–119.
48. Post RM. Special issues of research methodology in bipolar clinical treatment trials. In: Hertzman M, Alder L, eds. *Clinical Trials in Psychopharmacology: A Better Brain*, Second Edition. Chichester, United Kingdom: Wiley-Blackwell Publishing; 2010:149–177.